Muna Therapeutics Initiates Phase 1 Trial with First Participants Dosed for Novel Oral TREM2 Agonist Targeting Early Alzheimer’s Disease

Copenaghen (Denmark) – Golgi Neurosciences Srl is pleased to announce that its portfolio company Muna Therapeutics, a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases, has initiated a Phase 1 clinical study of its lead program MNA-001 in healthy adult participants.

MNA-001 is an orally administered small molecule agonist of the triggering receptor expressed on myeloid cells 2 (TREM2), designed to enhance the brain innate protective mechanisms. By activating TREM2, MNA-001 promotes microglial-mediated clearance of toxic proteins and cellular debris, aiming to slow or halt disease progression in Alzheimer’s and other neurodegenerative disorders.

The randomized, double-blind, placebo-controlled Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of MNA-001, as well as pharmacodynamic biomarkers of TREM2 activation in plasma and cerebrospinal fluid. Topline results are expected in late summer 2026.

Golgi Neurosciences congratulates the Muna Therapeutics team on achieving this important milestone in advancing disease-modifying therapies for neurodegeneration.

For more information, please visit Muna Therapeutics website or Golgi Neurosciences Linkedin page.